We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+2.78%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.04B
AUM Growth
-$13.5M
Cap. Flow
+$810K
Cap. Flow %
0.08%
Top 10 Hldgs %
35.44%
Holding
98
New
14
Increased
36
Reduced
31
Closed
5

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$31.8M
2
DHR icon
Danaher
DHR
+$9.47M
3
EW icon
Edwards Lifesciences
EW
+$8.63M
4
ELV icon
Elevance Health
ELV
+$8.62M
5
GILD icon
Gilead Sciences
GILD
+$7.44M

Top Sells

Rank Stock Value
1
CI icon
Cigna
CI
+$21.7M
2
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$20.8M
3
THC icon
Tenet Healthcare
THC
+$18.2M
4
MDT icon
Medtronic
MDT
+$9.59M
5
ZBH icon
Zimmer Biomet
ZBH
+$8.91M

Sector Composition

Rank Sector Weight
1 Healthcare 99.92%
2 Industrials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRVA icon
76
Privia Health
PRVA
$2.86B
$1.98M 0.19%
114,000
– –
IMCR icon
77
Immunocore
IMCR
$1.73B
$1.98M 0.19%
58,278
-21,500
-27% -$1.1M
IDYA icon
78
IDEAYA Biosciences
IDYA
$3.54B
$1.88M 0.18%
+53,500
New +$2.12M
RVNC
79
DELISTED
Revance Therapeutics, Inc.
RVNC
$1.8M 0.17%
701,707
– –
INMB icon
80
INmune Bio
INMB
$58.8M
$1.57M 0.15%
178,284
– –
RLAY icon
81
Relay Therapeutics
RLAY
$4.37B
$1.5M 0.14%
230,000
– –
TECH icon
82
Bio-Techne
TECH
$11.2B
$1.43M 0.14%
20,000
+4,000
+25% +$294K
XENE icon
83
Xenon Pharmaceuticals
XENE
$6.21B
$1.36M 0.13%
+35,000
New +$1.4M
IGMS
84
DELISTED
IGM Biosciences
IGMS
$1.34M 0.13%
195,000
– –
AMGN icon
85
Amgen
AMGN
$226B
$1.33M 0.13%
4,250
– –
PLRX icon
86
Pliant Therapeutics
PLRX
$64.4M
$1.29M 0.12%
120,250
-25,000
-17% -$322K
AVTR icon
87
Avantor
AVTR
$9.29B
$1.27M 0.12%
60,000
-111,000
-65% -$2.67M
RGEN icon
88
Repligen
RGEN
$9.21B
$1.26M 0.12%
10,000
+5,000
+100% +$784K
MEDP icon
89
Medpace
MEDP
$16.8B
$1.03M 0.1%
+2,500
New +$990K
NARI
90
DELISTED
Inari Medical, Inc. Common Stock
NARI
$963K 0.09%
20,000
-36,420
-65% -$1.61M
EVH icon
91
Evolent Health
EVH
$444M
$956K 0.09%
+50,000
New +$1.28M
AUGX
92
DELISTED
Augmedix, Inc. Common Stock
AUGX
$880K 0.08%
1,000,000
+200,000
+25% +$412K
BRKR icon
93
Bruker
BRKR
$8.58B
$383K 0.04%
6,000
-14,000
-70% -$1.05M
NTLA icon
94
Intellia Therapeutics
NTLA
$1.68B
– –
-48,000
Closed -$1.32M
NVCR icon
95
NovoCure
NVCR
$2.02B
– –
-495,307
Closed -$7.74M
ZBH icon
96
Zimmer Biomet
ZBH
$18.7B
– –
-67,500
Closed -$8.91M
SWAV
97
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
– –
-64,000
Closed -$20.8M
ALPN
98
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-85,500
Closed -$3.39M
1 2 3
4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2024 Portfolio in Review

As of Q2 2024, Rhenman & Partners Asset Management held 98 positions worth $1.04B, down 1.3% from $1.06B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Rhenman & Partners Asset Management's Q2 2024 filing shows 14 new, 36 increased, 31 reduced and 5 closed positions. Its largest new stake was Edwards Lifesciences: 97,500 shares worth $9.01M. The largest sale was Cigna, an estimated $21.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Industrials.

  • Rhenman & Partners Asset Management's largest Q2 2024 buy was Edwards Lifesciences: 97,500 shares worth $9.01M.
  • Rhenman & Partners Asset Management added most to UnitedHealth in Q2 2024, an estimated $31.8M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2024 reduction was Cigna, cutting an estimated $21.7M.
  • Rhenman & Partners Asset Management fully exited Shockwave Medical, Inc. Common Stock in Q2 2024, selling an estimated $20.8M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 35% of its $1.04B portfolio in Q2 2024.
  • Rhenman & Partners Asset Management opened 14 new positions and closed 5 in Q2 2024.
  • Rhenman & Partners Asset Management's portfolio value fell 1.3% quarter-over-quarter to $1.04B.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2024, filed 13 Aug 2024.